172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors
Immuno-Oncology and Technology · 2022-12 · 16 · 100284
DOI: 10.1016/j.iotech.2022.100284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immuno-Oncology and Technology, 2022-12. Verfasst von K. Papadopoulos und 19 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
JTX-8064, a highly selective and potent IgG4 inhibitor of myeloid-specific Leukocyte Immunoglobulin Like Receptor B2 (LILRB2), leads to macrophage reprogramming from an immunosuppressive to an immune activated state, resulting in T cell activation. INNATE (NCT04669899) is a phase (P) 1/2 dose escalation/expansion study of two investigational agents, JTX-8064 monotherapy (mono) and combination (combo) with pimi. P1 data defining Recommended P2 Dose (RP2D) are presented.
Zitieren
APA
Papadopoulos, K., Li, T., Lakhani, N., Powderly, J., George, T., Teoh, D., Kilari, D., Giaccone, G., Sanborn, R., Ghamande, S., LoRusso, P., Gibney, G., Ma, V., Yalamanchili, K., Brown, J., Mota, N., Kadra, C. T., Umiker, B., Xiao, X., & Trehu, E. (2022). 172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors. Immuno-Oncology and Technology, 16, 100284. https://doi.org/10.1016/j.iotech.2022.100284
Vancouver
Papadopoulos K, Li T, Lakhani N, Powderly J, George T, Teoh D, et al. 172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors. Immuno-Oncology and Technology. 2022;16:100284. doi:10.1016/j.iotech.2022.100284
BibTeX
@article{Papadopoulos2022,
author = {Papadopoulos, K. and Li, T. and Lakhani, N. and Powderly, J. and George, T. and Teoh, D.G.K. and Kilari, D. and Giaccone, G. and Sanborn, R.E. and Ghamande, S. and LoRusso, P. and Gibney, G. and Ma, V.T-L. and Yalamanchili, K. and Brown, J. and Mota, N. and Kadra, C. Tasillo and Umiker, B. and Xiao, X. and Trehu, E.},
title = {172P Phase I study of JTX-8064, a LILRB2 (ILT4) inhibitor, as monotherapy and combination with pimivalimab (pimi), a PD-1 inhibitor (PD-1i), in patients (pts) with advanced solid tumors},
journal = {Immuno-Oncology and Technology},
year = {2022},
volume = {16},
pages = {100284},
doi = {10.1016/j.iotech.2022.100284}
}
EUVIMED